Pharvaris N.V. Price & Performance (PHVS)

Pharvaris reported a Q4 loss of €34.76 million, or €0.64 per share, outperforming analyst forecasts of a €0.72 loss. Despite zero revenue, shares have fallen 31% year-to-date. Analyst sentiment remains positive, with a consensus 'buy' rating and a median 12-month price target of $32.12

Pharvaris reached targeted enrollment for its RAPIDe-3 Phase 3 trial of deucrictibant for hereditary angioedema treatment. The company also received European orphan drug designation for the therapy. FY2024 saw a net loss of €134 million, with cash reserves at €281 million as R&D spending increased.34

Recent filings reveal new institutional investments in Pharvaris, with Rock Springs Capital Management acquiring 18,200 shares. The stock is trading near its 52-week low, but analysts continue to forecast growth, maintaining a 'market outperform' rating and a price target increase to $55 by JMP Securities.56